Latest Kaiser Health News Stories
KHN correspondent Shefali Luthra answered a wide variety of questions about health care in a Reddit “Ask Me Anything” chat.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and new podcast panelist Anna Edney of Bloomberg News discuss this week’s spate of speeches by the leaders of the Department of Health and Human Services. They also discuss the slow progress on health legislation on Capitol Hill intended to fund the government and stabilize the individual insurance market. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
The market is flooded with 28 different medications for just 20,000 patients with the hereditary bleeding disorder. Yet intense competition hasn’t worked to bring costs down. Sales amount to $4.6 billion annually in the U.S.
Saving the lives of people with the bleeding disorder can require high doses of expensive blood-clotting factor. Taxpayers foot much of the bill as manufacturers profit enormously.
California’s health insurers trotted out a heart-healthy character with an ulterior motive — taking a dig at drugmakers.
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discusses drug costs with Scott Simon, the host of NPR’s Weekend Edition. Listen to the broadcast and read a transcript of that conversation.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Margot Sanger-Katz of The New York Times discuss the health policy changes included in the just-concluded bipartisan budget deal on Capitol Hill. The panelists also talk about the final enrollment numbers for individual insurance purchased under the Affordable Care Act, and possible drug price proposals in President Donald Trump’s upcoming budget. Plus, Rovner interviews Andy Slavitt, who this week launched a health care advocacy group called “The United States of Care.”
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo and Julie Appleby and Sarah Jane Tribble of Kaiser Health News discuss President Donald Trump’s promises to reduce drug prices in his first State of the Union Address. The panelists also discuss the departure of the director of the Centers for Disease Control and Prevention after conflict-of-interest reports and the efforts by some states to flout the Affordable Care Act.
Amazon, Berkshire Hathaway and JPMorgan Chase & Co. are partnering up to address employee health care costs and improve satisfaction. Can they deliver? And would repackaging health insurance involve drones?
Although the potentially fatal disease is common among the incarcerated, treatment with the latest hepatitis drugs isn’t.
In this episode of “What The Health?” — taped before a live audience — panelists discuss the potential federal government shutdown and what may be in store for health in 2018. They are joined by former Medicare and Medicaid head Tom Scully.
Orders for potassium iodide reportedly jumped after a Jan. 2 war of words between Trump and North Korea’s Kim Jong-un.
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases — but he intends to work on that problem.
This doctor came out of retirement with the goal of treating every patient at high risk for hepatitis C he encounters. The problem is finding them.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.